Physician profile
Ginny Leva
NPI 1386680478
$7,635.58
in general payments reported to CMS, 2019-2025
18 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,577 · 2020: $310 · 2021: $397 · 2022: $402 · 2023: $820 · 2024: $520 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apyx Medical Corporation | $3,405.06 | 2019-2020 | |
| Merz North America, INC. | $2,439.83 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $402.20 | 2019 | |
| Revance Therapeutics, INC. | $280.57 | 2024-2025 | Daxxify |
| Novo Nordisk INC | $250.01 | 2023-2024 | Wegovy |
| Amarin Pharma, INC. | $201.35 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $162.94 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $144.16 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $125.08 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $43.43 | 2023 | Trelegy Ellipta |
| Acelrx Pharmaceuticals, INC. | $39.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $37.90 | 2023 | Quviviq |
| Philips North America LLC | $19.70 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.09 | 2023 | Dsuvia |
| Biohaven Pharmaceuticals, INC. | $17.69 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.21 | 2023 | Livalo, Seglentis |
| Allergan, INC. | $15.89 | 2019 | |
| Bioxcel Therapeutics, INC. | $14.72 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginny Leva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.